Ascendis Pharma AS
$ 218.82
-2.36%
01 Jun - close price
- Market Cap 13,518,646,000 USD
- Current Price $ 218.82
- High / Low $ 227.27 / 217.57
- Stock P/E 24.87
- Book Value 9.16
- EPS 8.80
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE 0.33 %
- 52 Week High 250.74
- 52 Week Low 160.86
About
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Analyst Target Price
$297.76
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-11 | 2025-11-12 | 2025-08-07 | 2025-05-01 | 2025-02-12 | 2024-11-14 | 2024-09-03 | 2024-05-02 | 2024-02-07 | 2023-11-07 | 2023-08-16 |
| Reported EPS | 0.27 | -0.55 | -1 | -0.64 | -1.58 | -0.64 | -1.72 | -2.11 | -2.3 | -1.54 | -2.88 | -2.16 |
| Estimated EPS | 0.43 | -0.24 | -0.16 | -1.31 | -1.51 | -0.93 | -1.49 | -1.46 | -1.42 | -1.76 | -2.25 | -2.59 |
| Surprise | -0.16 | -0.31 | -0.84 | 0.67 | -0.07 | 0.29 | -0.23 | -0.65 | -0.88 | 0.22 | -0.63 | 0.43 |
| Surprise Percentage | -37.2093% | -129.1667% | -525% | 51.145% | -4.6358% | 31.1828% | -15.4362% | -44.5205% | -61.9718% | 12.5% | -28% | 16.6023% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASND
2026-06-02 20:24:46
Ascendis Pharma A/S's EVP & Chief Financial Officer, Scott Thomas Smith, purchased 100 Ordinary Shares in an open-market transaction on June 2, 2026, at $219.00 per share. This transaction increases his direct holdings to 4,367 Ordinary Shares. The insider trade shows a positive sentiment with a net purchase of $21,900.
2026-06-01 20:10:58
Ascendis Pharma A/S's EVP & Chief Financial Officer, Scott Thomas Smith, has filed an amended Form 3 detailing his equity holdings in the company. The filing indicates he directly owns 4,017 Ordinary Shares, along with Restricted Stock Units (RSUs) covering 9,552, 3,197, and 4,246 Ordinary Shares, which begin vesting on March 1, 2027. Additionally, he holds fully vested and exercisable warrants for a total of 154,259 Ordinary Shares, with exercise prices ranging from $37.18 to $176.28 and expiration dates between 2027 and 2031, with this filing serving as an update to his holdings rather than reflecting new transactions.
2026-06-01 20:10:58
Ascendis Pharma A/S director Jean Jacques Bienaime recently purchased 500 Ordinary Shares through three open-market transactions on May 29, 2026, with prices ranging from $222.30 to $223.76 per share. Following these buys, Bienaime directly holds 600 Ordinary Shares of Ascendis Pharma. This transaction was reported in a Form 4 SEC filing, indicating a net-buy of 500 shares with no sales.
2026-05-30 20:09:55
Ascendis Pharma (ASND) is analyzed as undervalued by 12.1% with earnings forecasted to grow by 16.93% annually. The company recently became profitable and analysts expect a 33.3% rise in stock price. Recent news includes FDA approval for YUVIWEL, strong commercial traction for other products, and a significant insider stock sale.
2026-05-27 19:40:42
Ascendis Pharma A/S director Jean Jacques Bienaimé recently purchased 400 Ordinary Shares of the company in two open-market transactions on May 26, 2026. The shares were bought at weighted average prices of $236.235 and $239.3675 per share, totaling approximately $95,121. This insider activity indicates a net buy position, increasing his direct holdings to 400 shares, as detailed in a recent Form 4 SEC filing.
2026-05-27 06:10:30
This article provides comprehensive financial data for Ascendis Pharma A/S (ASND), including its latest stock price, key financial ratios, performance metrics over various periods, and upcoming earnings dates. It also lists recent analyst ratings and a detailed timeline of news and press releases related to the company's drug development, regulatory approvals, and financial reports. Additionally, the article includes insider transaction data for executives and directors.
